Regeneron Pharmaceuticals

Business

Harmony CFO's Complete Stock Sale Raises Eyebrows Amid Upbeat Revenue Forecasts

Harmony Biosciences CFO Sandip Kapadia has liquidated his entire direct stake in the company, a move that contrasts sharply with the firm's robust financial performance and bullish $1 billion revenue target for its flagship drug WAKIX by 2026. While the sales were pre-planned, the timing fuels debate on insider confidence versus corporate optimism.

Feb 2, 2026

Business

FDA Expands Glaukos' iDose TR Implant Approval, Paving Way for Repeat Use in Glaucoma Management

Glaukos Corporation secures a significant FDA nod allowing repeated administration of its sustained-release iDose TR implant, broadening treatment options for patients with glaucoma and potentially reshaping long-term care paradigms.

Feb 2, 2026

Business

Amgen Earnings Preview: Biotech Giant Faces Growth Test Amid Market Scrutiny

As Amgen prepares to release its fourth-quarter results, investors are watching for signs of sustained momentum in its key drug portfolios and the impact of recent acquisitions.

Feb 2, 2026

Business

Bayer's Stock Soars 107% in a Year: Is the Pharma Giant Still Undervalued?

Bayer's share price has more than doubled in the past 12 months, yet key valuation models suggest a significant gap remains between its market price and intrinsic value. We examine the metrics behind the rally and the lingering legal and portfolio challenges facing the company.

Feb 2, 2026

Business

Johnson & Johnson Poised to Join $100 Billion Sales Club, Defying Industry Headwinds

The healthcare behemoth's robust 2025 results and 2026 guidance signal a landmark year ahead, as it navigates patent expirations and pricing pressures while maintaining its coveted dividend king status.

Jan 31, 2026

Business

AstraZeneca's Valuation Puzzle: Strong Pipeline and Steady Gains Mask Undervalued Opportunity?

Despite a robust drug pipeline and steady long-term gains, AstraZeneca's recent share price stagnation has investors questioning its true worth. A deep dive into valuation models suggests the pharmaceutical giant may be trading at a significant discount to its intrinsic value, even as its P/E ratio appears elevated compared to peers.

Jan 31, 2026

Business

Olin's Q4 2025 Earnings Fall Short Amid Operational Woes and Market Slump; Management Outlines Cost-Cutting Path

Chemical and ammunition manufacturer Olin Corporation reported fourth-quarter results that missed internal forecasts, pressured by plant disruptions, supply issues, and a sharp year-end drop in chlorine demand. Executives emphasized cash preservation and cost control while navigating what they term an extended market downturn.

Jan 31, 2026

Business

Tilray Brands: A Value Play After Steep Declines, or a Value Trap?

As Tilray Brands' stock languishes near multi-year lows, a deep dive into its valuation metrics suggests a significant discount. But with the cannabis sector facing headwinds, is this a genuine opportunity for investors, or a sign of deeper troubles?

Jan 30, 2026

World

Trump Declares National Emergency Over Cuba, Threatens Tariffs on Oil Suppliers; Strikes New Trade Deal with Guatemala

The Trump administration has escalated pressure on Cuba by declaring a national emergency and threatening punitive tariffs on countries supplying it with oil, while simultaneously finalizing a reciprocal trade agreement with Guatemala aimed at bolstering Western Hemisphere supply chains.

Jan 30, 2026

Business

Beyond the Hype: Three Healthcare Stocks Facing Headwinds in a Booming Sector

While the healthcare sector has significantly outperformed the broader market, surging 17.4% in six months, not all companies are positioned to thrive. Intense competition and shifting market dynamics pose risks for some established players. We examine three stocks where investors may want to exercise caution.

Jan 30, 2026

Business

Healthcare Sector Outperforms, But Investors Must Navigate Regulatory Crosscurrents

While the healthcare sector has surged 17.4% in six months, outpacing the S&P 500, regulatory headwinds and valuation concerns demand a selective approach. We examine one stock with a durable edge and two facing significant challenges.

Jan 30, 2026

Business

Reed Jobs Launches $200M+ Venture Fund Aiming to Turn Cancer into a Manageable Condition

Reed Jobs, son of the late Apple co-founder Steve Jobs, has secured over $200 million for Yosemite, a venture fund dedicated to pioneering cancer treatments. Backed by major institutions, the fund seeks to transform cancer from a fatal diagnosis to a chronic, manageable disease within a generation.

Jan 30, 2026

Business

Therapeutics Sector Shows Resilience in Q3: United Therapeutics Lags as Halozyme and Biogen Outperform

A mixed third-quarter earnings season for therapeutics stocks reveals divergent paths, with United Therapeutics missing estimates while peers like Halozyme and Biogen post strong beats. Sector-wide revenue growth and positive stock reactions suggest underlying investor confidence despite regulatory and pricing headwinds.

Jan 30, 2026

Business

Analysts Trim Targets but See Steady Growth Ahead for Abbott Laboratories

Despite near-term headwinds in its Nutrition segment, Abbott Laboratories (ABT) maintains a bullish long-term outlook with solid organic sales growth projected for 2026, even as major analysts adjust their price targets following Q4 results.

Jan 30, 2026

Business

Eli Lilly Bets $3.5 Billion on Pennsylvania as Pharma Giants Shift Production Stateside

Eli Lilly announces a massive new manufacturing facility in Pennsylvania, part of a strategic pivot by major drugmakers to onshore production amid trade tensions and soaring demand for weight-loss drugs.

Jan 30, 2026

Business

FDA Greenlights Spectrum Dynamics' AI-Powered Imaging Platform, Boosting Nuclear Medicine Precision

The FDA clearance of Spectrum Dynamics' Veritas.AI platform marks a significant step forward for nuclear imaging, promising to cut scan times in half and enhance image clarity for critical applications like cancer theranostics.

Jan 30, 2026

Business

AstraZeneca Bets $18.5 Billion on CSPC's Monthly Obesity Shot in Major Pipeline Push

In a landmark deal, AstraZeneca has licensed a suite of next-generation weight-loss drugs from China's CSPC, aiming to challenge the dominance of Lilly and Novo Nordisk with longer-acting monthly injectables.

Jan 30, 2026

Business

Altor Solutions Hits Major Sustainability Milestone, Diverts Over One Million Pounds of EPS from Landfills

The protective packaging leader's 2025 recycling achievement, driven by customer partnerships and its EmeraldPak product, marks a significant step in its 'Stairway to Green' initiative and underscores growing industry momentum for closed-loop systems.

Jan 30, 2026

World

UK-China Relations Thaw as Starmer Seeks Economic Reset Amid Global Trade Shifts

Prime Minister Keir Starmer's landmark visit to Beijing marks a cautious pivot in UK-China relations, yielding agreements on tariffs, visas, and green energy. But can British businesses navigate the opportunities and challenges of re-engagement?

Jan 30, 2026

Business

United Rentals Caps Record 2025, Eyes Another Year of Growth Fueled by Mega-Projects

United Rentals reported strong Q4 results, driven by data center and power sector demand, and issued 2026 guidance forecasting continued revenue growth. Management highlighted a robust project pipeline while navigating margin pressures.

Jan 30, 2026